|
| Species | KEGG terms | Benjamini |
|
| E. coli | Metabolic pathways | 3.30-08 |
| Biosynthesis of amino acids | 1.00-06 |
| Biosynthesis of secondary metabolites | 2.40-04 |
| Biosynthesis of antibiotics | 7.40-04 |
| Lysine biosynthesis | 3.30-03 |
|
| H. sapiens | Biosynthesis of antibiotics | 3.70-10 |
| Metabolic pathways | 2.80-09 |
| Ribosome | 3.40-08 |
| Valine, leucine, and isoleucine degradation | 1.30-06 |
| Carbon metabolism | 6.20-06 |
| Oxidative phosphorylation | 1.10-05 |
| Parkinson’s disease | 2.60-05 |
| Citrate cycle (TCA cycle) | 1.00-04 |
| Huntington’s disease | 4.10-04 |
| Alzheimer’s disease | 7.80-04 |
| Aminoacyl-tRNA biosynthesis | 1.00-03 |
| Butanoate metabolism | 3.40-03 |
| Proteasome | 8.20-03 |
|
| M. musculus | Metabolic pathways | 6.20-26 |
| Parkinson’s disease | 8.50-11 |
| Oxidative phosphorylation | 3.40-10 |
| Nonalcoholic fatty liver disease (NAFLD) | 1.00-09 |
| Huntington’s disease | 2.80-09 |
| Alzheimer’s disease | 1.40-08 |
| Ribosome | 3.30-07 |
| Peroxisome | 1.80-06 |
| Glycine, serine, and threonine metabolism | 1.50-05 |
| Pyruvate metabolism | 9.00-05 |
| Propanoate metabolism | 2.40-04 |
| Valine, leucine, and isoleucine degradation | 1.90-03 |
| Glyoxylate and dicarboxylate metabolism | 3.10-03 |
| Biosynthesis of antibiotics | 5.60-03 |
|
| M. tuberculosis | Metabolic pathways | 1.00-04 |
| Microbial metabolism in diverse environments | 2.50-04 |
| Biosynthesis of antibiotics | 4.40-04 |
| Biosynthesis of secondary metabolites | 1.00-02 |
| Propanoate metabolism | 1.00-02 |
|
| S. cerevisiae | Metabolic pathways | 5.20-05 |
| Biosynthesis of amino acids | 3.30-04 |
| 2-Oxocarboxylic acid metabolism | 7.90-04 |
| Biosynthesis of antibiotics | 3.50-03 |
| Oxidative phosphorylation | 3.50-03 |
|
